Tinninus Assessment Technology

MENODYS announces the recruitment of the last patient in a proof of concept comparing its Tinnitus Assessment Technology to the current standard method of evaluating tinnitus

Longueuil, Quebec, Canada – Pr. Sylvie Hébert of the School of Speech Pathology and Audiology at the University of Montreal has completed the recruitment of a proof of concept named MENODYS-INNOV, a research project comparing an innovative technological approach for the objective assessment of tinnitus developed by MENODYS to the standard currently used method of psychoacoustic pitch and loudness measurement used by audiology clinicians around the world. 31 patients with established diagnosis of bilateral tinnitus for at least 6 months were evaluated twice (2 visits) separated by 30 days by 2 different audiologists using during each visit, 2 different methods of evaluation of the tinnitus pitch and loudness. The study objectives are as follow: 1) demonstrating the advantage of the MENODYS tinnitus evaluation method to objectively assess tinnitus in pitch and loudness; 2) demonstrating the advantage of the MENODYS tinnitus evaluation method in terms of time requirement (speed of the test) for the audiologist and the patient; 3) demonstrating the value of assessing high frequencies (above 8000 Hz) in tinnitus assessment procedures; 4) demonstrating the value of the MENODYS tinnitus evaluation method for its capacity to define the best tinnitus symptom attenuation protocol (better adjustment of hearing aids and sound generators); and 5) demonstrating the value of the MENODYS tinnitus evaluation method in terms of test-retest accuracy (a tool to follow–up patients over time on the benefits of tinnitus symptoms attenuation protocols).

“This study was launched to demonstrate the importance for audiology professionals around the world, dealing with tinnitus patients, to have access to a rapid, objective, reproducible, and precise tinnitus assessment technology”, said Richard Côté, Executive Vice President of MENODYS.

Tinnitus is an important and growing worldwide health issue in audiology affecting more than 360 000 Canadians, 30 million Americans and more than 120 million Europeans.

About MENODYS

MENODYS is a Canadian company specialized in the development and commercialization of medical technologies. www.menodys.com

Tinninus Assessment Technology

MENODYS announces the publication in Frontiers in Neurology of the clinical validation results of its Tinnitus Assessment Technology

Longueuil, Quebec, Canada – MENODYS announces that the results of the clinical validation of its tinnitus assessment technology (TAT) have been accepted for publication in the February 2017 edition of the journal “Frontiers in Neurology”. Invented by Pr. Sylvie Hébert and Mr. Philippe Fournier of the School of Speech Pathology and Audiology at the University of Montreal, the TAT offers audiology specialists around the world a rapid and innovative approach to objectively assess the frequency and amplitude of their patient’s tinnitus. Current clinical assessment of tinnitus relies mainly on self-report. Psychoacoustic assessment of tinnitus pitch and loudness are recommended but methods yield variable results. The published results report that a previously validated fixed laboratory-based method and a newly developed clinically-relevant portable prototype (MENODYS TAT) yield comparable results in the assessment of psychoacoustic tinnitus pitch and loudness. The clinical validation identified that despite differences in the devices’ physical presentations, likeness and loudness ratings were globally consistent between the two methods and, moreover, highly reproducible from one method to the other on the subjects tested. All in all, both methods yielded robust tinnitus data in less than 12 minutes, with the MENODYS TAT having the advantage of not being dependent of learning effects, being user-friendly, and being adaptable to the audiogram of each patient to further reduce testing time.

“This publication confirms the successful transformation of a University-based concept into a commercially ready medical technology that will modify the way patients with tinnitus can precisely define the nature of their tinnitus in both frequency and loudness, in less than 12 minutes. The MENODYS TAT thus offers an innovative tool for audiology specialists to objectively define tinnitus and follow up regularly on the benefit of the prescribed tinnitus symptom attenuation protocol”, said Richard Côté, Executive Vice President of MENODYS.

Tinnitus is an important health issue in audiology affecting more than 360 000 Canadians, 30 million Americans and more than 120 million Europeans.

About MENODYS

MENODYS is a Canadian company specialized in the development and commercialization of medical technologies. www.menodys.com

Tinninus Assessment Technology

MENODYS’s Tinnitus Assessment Technology featured in medGadget’s Ear, Nose and Throat Diagnostic and Surgical Devices Pipeline Review, 2015

Longueuil, Quebec, Canada – MENODYS and its Tinnitus Assessment Technology are featured in the Ear, Nose and Throat Diagnostic and Surgical Devices Pipeline Review, 2015 of medGadget, the web-based medical technology news source, dated September 18th 2015. Exclusively licenced to MENODYS and invented by Pr Sylvie Hébert and Philippe Fournier of the School of Speech Pathology and Audiology of the University of Montreal, the Tinnitus Assessment Technology offers audiology specialists around the world a faster and objective approach to assess the frequency spectrum and amplitude of their patient’s tinnitus. This medical technology will thus allow audiology specialists to better design the symptoms attenuation protocol of the patient’s tinnitus.

“Being part of such international market research studies is a confirmation of our business model of bringing innovative medical technology ideas to the market and for international medical device companies to take on their commercialization. We have recently completed the development and validation of the technology and we have initiated discussions with possible commercialization partners with the hope of quickly bringing this innovative approach in audiology to the growing worldwide population suffering from tinnitus”, said Richard Côté, Executive Vice President of MENODYS.

Tinnitus is an important health issue in audiology affecting more than 360 000 Canadians, 30 million Americans and more than 120 million Europeans.

About MENODYS

MENODYS is a Canadian company specialized in the development and commercialization of medical technologies. www.menodys.com

 

 

Tinninus Assessment Technology

MENODYS launches the clinical validation of its Tinnitus Assessment Technology

Longueuil, Quebec, Canada – MENODYS is proud to announce the launch of the clinical validation phase of its tinnitus assessment technology.

This important milestone is reached following the successful completion of prototypes enabling the assessment of tinnitus based on the developed university bench version. Invented by Pr Sylvie Hébert and Philippe Fournier of the School of Speech Pathology and Audiology at the University of Montreal, the device will offer audiology specialists around the world a rapid and innovative approach to objectively assess the frequency and amplitude of their patient’s tinnitus. This medical technology will thus allow audiology specialists to precisely design the symptom attenuation protocol for the patient’s tinnitus. The clinical validation will involve adults suffering from tinnitus and will be performed at the department of audiology of the University of Montreal, Quebec, Canada.

“We are excited with the rapid development process of this much needed medical device innovation for an important unmet need in audiology. This clinical validation will confirm the published results of this new technological concept and bring us a step closer to offering this innovation worldwide to tinnitus patients and audiology professionals”, said Richard Côté, Executive Vice President of MENODYS.

Tinnitus is an important health issue in audiology affecting more than 360 000 Canadians, 30 million Americans and more than 120 million Europeans.

About MENODYS

MENODYS is a Canadian company specialized in the development and commercialization of medical technologies. www.menodys.com

Tinninus Assessment Technology

MENODYS launches the prototyping of its Tinnitus Assessment Technology

Longueuil, Quebec, Canada – MENODYS is proud to announce the launch of the prototyping phase of its tinnitus assessment technology. Invented by Pr Sylvie Hébert and Philippe Fournier of the School of Speech Pathology and Audiology of the University of Montreal, the device will offer audiology specialists around the world an innovative approach to objectively assess the frequency and amplitude of tinnitus.

Tinnitus is an important health issue in audiology affecting more than 360 000 Canadians, 30 million Americans and more than 120 million Europeans.

“ We are excited to launch the development of the Tinnitus Assessment Technology, the third technology in MENODYS’ portfolio, which confirms the acceleration of our business plan of developing and commercializing innovations in the medical device sector” said René Gosselin, President at MENODYS.

About MENODYS

MENODYS is a Canadian company specialized in the development and commercialization of medical technologies. www.menodys.com

Tinninus Assessment Technology

MENODYS and Univalor announce the signature of an exclusive agreement to develop and commercialize an innovative technology for the objective assessment of tinnitus

Longueuil, Quebec, Canada – MENODYS and Univalor, the University of Montreal’s office of technology transfer, have agreed to the terms of an exclusive license option to a medical technology developed by Pr Sylvie Hébert, of the School of Speech Pathology and Audiology of the University of Montreal.

This technology offers a new approach for the objective assessment of the frequency and amplitude of tinnitus. Tinnitus is an important health issue in audiology affecting more than 360 000 Canadians and 30 millions Americans.

The agreement is the second to take place between Univalor and MENODYS will accelerate the development and marketing of a technology targeting a specific need. “We look forward to work again with MENODYS who proved to be a worthy partner in the commercialization of innovations in the sector of medical technology,” said Clermont Beaulieu, manager in Life Sciences at Univalor.

“ We are excited about this new agreement with Univalor which confirms our business model of accelerating the transfer and international commercialization of innovations in the medical device sector” said Richard Côté, Executive vice president at MENODYS.

About MENODYS

MENODYS is a Canadian company specialized in the development and commercialization of medical technologies. www.menodys.com

About Univalor

Univalor is a university technology transfer organization that has been commercializing scientific findings and technological innovations emanating from some 2,600 researchers at the Université de Montréal and its affiliated health centres, Polytechnique Montréal and HEC Montréal, in the areas of pure and applied sciences, engineering, information technology, management sciences, life sciences and human health. By creating links between the university and the business community, Univalor helps make businesses more competitive, generate revenue for research and, most importantly, enrich society. www.univalor.ca/en